Capricorn Fund Managers Ltd Takes $13.64 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Capricorn Fund Managers Ltd purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 868,417 shares of the company’s stock, valued at approximately $13,643,000. Takeda Pharmaceutical comprises 4.9% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 6th biggest position.

Several other large investors also recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Takeda Pharmaceutical by 171.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,904,296 shares of the company’s stock worth $60,907,000 after purchasing an additional 2,465,178 shares during the last quarter. Federated Hermes Inc. grew its holdings in Takeda Pharmaceutical by 106.7% in the 1st quarter. Federated Hermes Inc. now owns 601,629 shares of the company’s stock valued at $9,915,000 after buying an additional 310,512 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 8.7% in the 1st quarter. Sequoia Financial Advisors LLC now owns 21,189 shares of the company’s stock worth $349,000 after acquiring an additional 1,692 shares during the last quarter. SYSTM Wealth Solutions LLC purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter worth $192,000. Finally, Seven Eight Capital LP acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $181,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK stock opened at $16.32 on Tuesday. Takeda Pharmaceutical Company Limited has a 52-week low of $12.28 and a 52-week high of $17.15. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 0.63. The stock has a market cap of $51.65 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 7.34 and a beta of 0.62. The business has a fifty day moving average of $15.38 and a two-hundred day moving average of $15.96.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.55 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 12.54% and a net margin of 7.34%. The firm had revenue of $7.71 billion during the quarter. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 0.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. cut their price objective on shares of Takeda Pharmaceutical from $14.20 to $14.00 in a research report on Friday, September 1st.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.